Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLx-2101 in Secondary Raynaud's Disease
NCT00528242Phase 2Completed
- Sponsor
- Response Pharmaceuticals
- Start
- Jun 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of slx-2101 in Secondary Raynaud's Phenomenon, sponsored by Response Pharmaceuticals. Started Jun 2007; status: completed.
02
Drugs
slx-2101
03
Conditions
Secondary Raynaud's Phenomenon
Beyond the preview
Go deeper on NCT00528242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528242.